DGAP-News: InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development

DGAP-News: InflaRx GmbH / Key word(s): Financing
InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to
foster complement inhibitor development

21.07.2016 / 18:45
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to
foster complement inhibitor development

Jena, Germany, July 21, 2016 - InflaRx, the biopharmaceutical company
developing new therapeutics in the terminal complement space, announced
today that it has raised EUR 31 million (USD 34 million) in a Series C
round. The financing was composed of new investors such as Staidson
Hongkong Investment Company ltd. ("STS"), international industrial
investors and family offices as well as existing investors. Proceeds from
the round will be used to advance clinical phase II development of the lead
drug candidate IFX-1, a first-in-class monoclonal anti-complement C5a
antibody, in various acute and chronic inflammatory indications as well as
the preclinical development of the follow-up pipeline-molecules.

"InflaRx has made significant progress in the field of terminal complement
C5a inhibition, putting us in a lead position, globally. In January, we
validated IFX-1 in a Phase IIa clinical trial that provided excellent data.
This has been well accepted by our existing and new shareholders," said
Prof. Dr. Niels Riedemann, founder and CEO of InflaRx. "We will use the
proceeds of this Series C financing to develop our lead drug candidate
IFX-1 in different inflammatory disease indications with high unmet medical
need and orphan drug potential," he added.

In January 2016, InflaRx successfully completed its first clinical Phase
IIa trial in patients suffering from early septic organ dysfunction; all
primary clinical endpoints were met. In June 2016, the company initiated
its second phase II trial of IFX-1 in patients undergoing complex cardiac
surgery.

"We have established long standing research collaborations with
internationally recognized research groups in China and thus have built a
strong network in the region. This has helped us to attract STS as a major
new investor in our unique technology", Prof. Renfeng Guo, founder and CSO
of InflaRx stated.

"Despite the very challenging market conditions, we have been able to bring
together an international syndicate of investors and family offices that
believe in the tremendous potential of our technologies. The proceeds of
this financing will enable us to reach multiple significant value
inflection points and generate a variety of strategic options," commented
Arnd Christ, CFO of InflaRx.

About IFX-1: IFX-1 is a first-in-class monoclonal anti-complement C5a
antibody which offers a complete biological blocking activity and
selectivity towards its target, C5a. Thus, IFX-1 leaves the important
formation of the membrane attack complex (C5b-9) intact while being capable
of blocking C5a mediated effects in humans instantly and completely. IFX-1
controls the inflammatory response-driven tissue and organ damage by
specifically blocking C5a as a key "amplifier" of this response in
preclinical studies. IFX-1 is the first monoclonal anti-C5a antibody
introduced into clinical development and has thus far successfully
completed a clinical phase IIa study in patients suffering from septic
organ dysfunctions in which all primary endpoints were met. IFX-1 is
currently being developed in several different clinical indications.

About InflaRx: InflaRx is a biopharmaceutical company focusing on the
development of new breakthrough therapeutics controlling inflammation
resulting from terminal complement activation. Its lead drug, IFX-1, is a
first-in-class complement C5a inhibiting monoclonal antibody, which the
company believes holds vast potential as a game changer in inflammation.
The Company also is developing additional molecules, IFX-2 and IFX-3,
targeting chronic inflammation related diseases. InflaRx was founded in
2007 and is headquartered in Jena, Germany. The team consists of
internationally renowned experts in complement and clinical research.
InflaRx is financed by Staidson Hongkong Investment Company ltd, bm-t
Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various
international industrial and private investors.

Contacts:

InflaRx GmbH
Niels C. Riedemann - CEO
Arnd Christ - CFO
Email: info[at]inflarx.de
Tel: +49-3641-508180
www.inflarx.de

MC Services AG
Katja Arnold / Dr. Cora Kaiser / Shaun Brown
Email: inflarx[at]mc-services.eu
Tel: +49-89-210 2280

The Trout Group
Jennifer Porcelli / Thomas Hoffmann
Email: JPorcelli[at]troutgroup.com / thoffmann[at]troutgroup.com
Tel: +1 646 378 2900


---------------------------------------------------------------------------

21.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

484973 21.07.2016